Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Jürg Zimmermann"'
Autor:
Jürg Zimmermann
Publikováno v:
Future Medicinal Chemistry. 1:1395-1398
Dr Jürg Zimmermann is the inventor of the drug imatinib (Gleevec®, Glivec®), which entered the market in 2001 and revolutionized the treatment of chronic myelogenous leukemia. He talks to Future Medicinal Chemistry about his career as a medicinal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ebbf864aeb7a1a1d346994a8e78d634
https://doi.org/10.4155/fmc.09.115
https://doi.org/10.4155/fmc.09.115
Autor:
Andreas Marzinzik, Jürg Zimmermann, Hansjörg Lehmann, Roland Messer, Xavier Pelle, Robert Häner
Publikováno v:
Synlett. :2441-2444
The synthesis of natural product-like compounds on solid support is described. Starting from a readily accessible D-(-)-ribose derivative, a tricyclic scaffold is prepared in five steps. After coupling onto solid supportsbearing different substituent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8934ecc1c047a083e5b435fa601c686f
https://doi.org/10.1055/s-2005-872684
https://doi.org/10.1055/s-2005-872684
Publikováno v:
Journal of Peptide Science. 9:187-199
The synthesis of heterocyclic compounds containing the 7-membered ring system [1,4]diazepane-2,5-dione is described. The aim of this study was to elaborate the solid phase and solution synthesis of eight representatives of the cyclic scaffold and to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::204ee2badc3670099c0623ca9ec2d3e6
https://doi.org/10.1002/psc.445
https://doi.org/10.1002/psc.445
Publikováno v:
Journal of Combinatorial Chemistry. 5:188-196
A solid-phase synthesis of an array of indoles is reported. The key step in our approach involves a N-H insertion reaction of N-alkylanilines into a highly reactive polymer-bound rhodium carbenoid intermediate to yield the corresponding alpha-arylami
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::531294b78c1a9bbb13660cf67944a46b
https://doi.org/10.1021/cc020079z
https://doi.org/10.1021/cc020079z
Autor:
Jürg Zimmermann
Publikováno v:
Nachrichten aus der Chemie. 50:1084-1090
Der Signalubertragungshemmstoff Glivec gehort zu einer neuen Generation von Designermedikamenten. Ursprunglich zur Therapie gegen eine Art von chronischer Leukamie entwickelt, wirkt die Substanz nicht wie die herkommlicher Therapien durch Zerstorung
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e4147a52d2a4ecf6a5f3ed23e0d36f1
https://doi.org/10.1002/nadc.20020501007
https://doi.org/10.1002/nadc.20020501007
Autor:
Doriano Fabbro, Paul W. Manley, Thomas Meyer, G. Fendrich, Pascal Furet, Sandra W. Cowan-Jacob, Elisabeth Buchdunger, Jürg Zimmermann
Publikováno v:
European Journal of Cancer. 38:S19-S27
The understanding of the pathophysiology of a large number of cancer types provides a strategy to target cancer cells with minimal effect on normal cells. Protein phosphorylation and dephosphorylation play a pivotal role in intracellular signaling; t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc43afd1a115b042ff0ff0a87bdf360e
https://doi.org/10.1016/s0959-8049(02)80599-8
https://doi.org/10.1016/s0959-8049(02)80599-8
Publikováno v:
Tetrahedron Letters. 43:5407-5410
A series of diverse polymer bound β-ketoesters have been prepared using a transesterification reaction between t-butyl β-ketoesters and a hydroxybutyl functionalized JandaJel resin. Additionally, these highly useful polymer bound substrates have al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a1429cd2bba8dcd4484d30b375d9a92f
https://doi.org/10.1016/s0040-4039(02)01076-6
https://doi.org/10.1016/s0040-4039(02)01076-6
Autor:
Sayuri Ohno-Jones, Martin Carroll, Elisabeth Buchdunger, Nicholas B. Lydon, Jürg Zimmermann, Shu Tamura, Brian J. Druker, D. Gary Gilliland
Publikováno v:
Blood. 90:4947-4952
CGP 57148 is a compound of the 2-phenylaminopyrimidine class that selectively inhibits the tyrosine kinase activity of the ABL and the platelet-derived growth factor receptor (PDGFR) protein tyrosine kinases. We previously showed that CGP 57148 selec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e1d3343e59e5334652e5823f85d0857
https://doi.org/10.1182/blood.v90.12.4947.4947_4947_4952
https://doi.org/10.1182/blood.v90.12.4947.4947_4947_4952
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 7:187-192
Due to its relatively clear etiology, Chronic myelogenous leukemia (CML) represents an ideal disease target for a therapy using a selective inhibitor of the Bcr-Abl tyrosine protein kinase. Extensive optimization of the class of phenylamino-pyrimidin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b1e5768e915b57625f3fc4d1fc58bf1b
https://doi.org/10.1016/s0960-894x(96)00601-4
https://doi.org/10.1016/s0960-894x(96)00601-4
Autor:
Shane Fanning, Nicholas B. Lydon, Sayuri Ohno, Elisabeth Buchdunger, Shu Tamura, Jürg Zimmermann, Brian J. Druker, Gerald M. Segal
Publikováno v:
Nature Medicine. 2:561-566
The bcr-abl oncogene, present in 95% of patients with chronic myelogenous leukemia (CML), has been implicated as the cause of this disease. A compound, designed to inhibit the Abl protein tyrosine kinase, was evaluated for its effects on cells contai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8dae900c797195cdc20db95b2404764
https://doi.org/10.1038/nm0596-561
https://doi.org/10.1038/nm0596-561